Evaxion Biotech A/S (EVAX) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Evaxion Biotech A/S (EVAX) Healthcare & Pipeline Overview

Evaxion Biotech A/S leverages artificial intelligence to develop innovative immunotherapies, targeting cancers and infectious diseases, positioning itself as a forward-thinking player in the biotechnology sector with a focus on cutting-edge treatments.

What Is the Investment Thesis for EVAX?

Evaxion Biotech A/S presents a compelling growth narrative driven by its innovative pipeline of AI-powered immunotherapies. The company's lead candidate, EVX-01, is currently in Phase IIb trials, with the potential to capture a significant share of the melanoma treatment market, valued at approximately $5 billion. Additionally, the ongoing development of EVX-02 and EVX-03 could further diversify revenue streams and enhance market presence. The company's unique AI-driven approach to drug development may lead to reduced timeframes in bringing products to market, a critical factor in the competitive biotech landscape. However, investors should be aware of risks associated with clinical trial outcomes and regulatory approvals, which could impact timelines and financial performance.

Based on FMP financials and quantitative analysis

EVAX Key Highlights

Market Cap of $19.6M reflects early-stage development and growth potential.

• P/E ratio of 94.75 indicates high investor expectations for future earnings growth.
• Gross margin of 100.0% highlights the potential for high profitability upon commercialization.
• Profit margin of -129.6% signifies current investment in R&D and clinical trials.
• Beta of 0.27 suggests lower volatility compared to the broader market.

Who Are EVAX's Competitors?

EVAX is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are EVAX's Key Strengths?

Innovative AI-driven approach to drug development.

• Strong pipeline with multiple candidates in various stages of clinical trials.
• Expertise in immunotherapy and vaccine development.

What Are EVAX's Weaknesses?

Current lack of revenue due to clinical-stage status.

• High operational costs associated with R&D and clinical trials.
• Limited market presence compared to larger competitors.

What Could Drive EVAX Stock Higher?

EVAX catalyst: Results from Phase IIb trials of EVX-01 are anticipated in Q4 2026, which could significantly impact market perception and stock performance.

• Development of EVX-02 in Phase IIa trials is progressing, with updates expected in mid-2026.
• Pre-clinical development of vaccine candidates EVX-B1, EVX-B2, and EVX-V1 is ongoing, with potential for future partnerships.

What Are the Key Risks for EVAX?

Financial-distress signal — its Altman Z-Score of -8.90 sits in the distress zone (elevated bankruptcy risk).

• Negative return on equity (-77.8%) — the business is not currently generating profit on shareholder capital.
• Clinical trial outcomes for EVX-01 and EVX-02 may not meet expectations, impacting future development plans.
• Regulatory hurdles and approval processes could delay product commercialization.
• Competition from established biotech firms could limit market share and pricing power.

What Are the Growth Opportunities for EVAX?

• Growth opportunity 1: Evaxion's lead candidate, EVX-01, is in Phase IIb trials for metastatic melanoma, a market expected to grow significantly due to increasing incidence rates. The melanoma treatment market is projected to reach $5 billion by 2027, providing substantial revenue potential for successful outcomes in clinical trials.
• Successful trials could position Evaxion as a key player in this lucrative segment.
• Growth opportunity 3: Evaxion's vaccine candidates, EVX-B1, EVX-B2, and EVX-V1, target bacterial and viral diseases, addressing a critical need in global health.
• Growth opportunity 4: The integration of AI in drug development can significantly reduce time-to-market and R&D costs, providing a competitive edge. As AI technology continues to evolve, Evaxion's capabilities in this area may enhance its position in the biotechnology sector.
• Growth opportunity 5: Strategic partnerships and collaborations with larger pharmaceutical companies could facilitate access to additional resources and expertise, accelerating the development and commercialization of Evaxion's therapies.

What Opportunities Does EVAX Have?

• Growing demand for innovative cancer treatments and vaccines.
• Potential for strategic partnerships to enhance development capabilities.
• Expansion into new therapeutic areas and geographic markets.

What Threats Does EVAX Face?

• Regulatory challenges and uncertainties in clinical trial outcomes.
• Intense competition from established biotech and pharmaceutical companies.
• Market volatility and funding challenges for clinical-stage companies.

What Are EVAX's Competitive Advantages?

• Unique AI-driven approach to immunotherapy development, differentiating Evaxion from competitors.
• Strong pipeline of innovative therapies targeting high-value markets.
• Expertise in both biotechnology and artificial intelligence, enhancing R&D capabilities.

What Does EVAX Do?

Evaxion Biotech A/S, founded in 2008 and headquartered in Hørsholm, Denmark, is a clinical-stage biotechnology company dedicated to developing artificial intelligence-powered immunotherapies. The company aims to address significant unmet medical needs in the treatment of cancers, bacterial diseases, and viral infections. Evaxion's innovative approach utilizes advanced AI algorithms to identify and develop novel therapeutic candidates, enhancing the efficiency and effectiveness of drug discovery. The company's flagship products include EVX-01, currently in Phase IIb clinical trials for metastatic melanoma, and EVX-02, which is in Phase IIa trials for adjuvant melanoma. Additionally, EVX-03 is a DNA-based immunotherapy aimed at treating various cancers. Beyond oncology, Evaxion is also advancing vaccine candidates EVX-B1, EVX-B2, and EVX-V1, which are in pre-clinical stages targeting bacterial and viral diseases. With a small team of 46 employees, Evaxion is positioned to capitalize on the growing demand for innovative treatments in the healthcare sector, particularly those that harness the power of artificial intelligence.

What Products and Services Does EVAX Offer?

• Develop artificial intelligence-powered immunotherapies for cancer and infectious diseases.
• Conduct clinical trials for innovative cancer treatments, including EVX-01 and EVX-02.
• Advance pre-clinical vaccine candidates targeting bacterial and viral infections.
• Leverage AI technology to enhance drug discovery and development processes.
• Focus on addressing unmet medical needs in oncology and infectious disease sectors.

How Does EVAX Make Money?

• Revenue generation primarily through the successful commercialization of therapeutics.
• Funding through partnerships, grants, and potential licensing agreements.
• Investment in R&D to develop innovative treatments with high market potential.
• Engagement in clinical trials to validate product efficacy and safety.

What Industry Does EVAX Operate In?

The biotechnology industry is experiencing robust growth, driven by advancements in technology and increasing demand for innovative therapies. The global biotechnology market is projected to reach approximately $2.4 trillion by 2028, with significant contributions from cancer immunotherapy and vaccine development. Evaxion Biotech A/S operates within this dynamic landscape, focusing on AI-driven solutions that differentiate it from traditional approaches. The competitive landscape includes established players and emerging companies, with a growing emphasis on precision medicine and personalized therapies.

Who Are EVAX's Key Customers?

• Healthcare providers and hospitals seeking advanced treatment options.
• Pharmaceutical companies interested in licensing innovative technologies.
• Patients with unmet medical needs in cancer and infectious diseases.

Company Profile

Evaxion Biotech A/S operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Horsholm, DK. The company is led by CEO Helen Katrina Tayton-Martin. EVAX has traded publicly since 2021.

Return on equity for Evaxion Biotech A/S stands at -77.8%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -34.4%, showing how much profit it generates from its asset base. A current ratio of 5.85 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -36.6%, the inverse of the P/E and a quick read on earnings relative to price.

EVAX Valuation & Market Position

With a $19.6M market cap, Evaxion Biotech A/S sits in the micro-cap segment of the market. Analyst price targets span from $9.00 to $16.00, with a consensus of $11.67. At the current price of $3.10, that implies approximately 276% upside potential. Relative to its peer group, EVAX's quantitative score of 22/100 is below the peer average of 80/100.

Quarterly Financial Performance: Evaxion Biotech A/S

Revenue for Evaxion Biotech A/S came in at $0 during Q2 FY2026. The company recorded a net loss of $3.7M, with diluted EPS of $-8.93. Quarter-over-quarter revenue has been mixed, typical for a micro-cap company operating in Healthcare. Across the four most recent quarters, EVAX averaged $-1.53 in diluted EPS.

Evaxion Biotech A/S's Piotroski F-Score is 5/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of -8.90 places it in the distress zone, a signal of elevated financial risk.

Evaxion Biotech A/S has beaten Wall Street's EPS estimate in 4 of its last 8 reported quarters — more hits than misses. Reported results have landed about 109.6% below estimates on average.

EVAX Financials

EVAX Latest News

EVAX Analyst Consensus

EVAX MoonshotScore

Common Questions About EVAX (Healthcare)

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources